PMID- 27238907
OWN - NLM
STAT- MEDLINE
DCOM- 20170502
LR  - 20170817
IS  - 1873-0442 (Electronic)
IS  - 1477-8939 (Linking)
VI  - 14
IP  - 5
DP  - 2016 Sep-Oct
TI  - Cost effectiveness of interferon-gamma release assay for tuberculosis screening 
      using three months of rifapentine and isoniazid among long-term expatriates from 
      low to high incidence countries.
PG  - 489-498
LID - S1477-8939(16)30043-6 [pii]
LID - 10.1016/j.tmaid.2016.05.010 [doi]
AB  - BACKGROUND: Long-term expatriates from low to high tuberculosis (TB) incidence 
      countries get high rates of active TB and latent TB infection (LTBI). TB 
      screening for expatriates is important for occupational health. Interferon-gamma 
      release assays are more accurate than tuberculin skin test (TST). Rifapentine 
      plus isoniazid for 3 months (3HP) is as effective as 9 months of isoniazid (9H) 
      with a higher treatment-completion rate. METHODS: Decision trees and Markov 
      models were constructed using a societal perspective on a lifetime horizon. The 
      target population was a hypothetical cohort of 30 year-old expatriates. Seven 
      strategies; TST with 3HP or 9H, QuantiFERON((R))-TB Gold In-Tube (QFT) with 3HP or 
      9H, T-SPOT((R)).TB (TSPOT) with 3HP or 9H and chest X-ray examination (CXR) were 
      modeled. The main outcome measure of effectiveness was quality-adjusted 
      life-years (QALYs) gained. RESULTS: QFT with 3HP yielded the greatest benefits 
      with the lowest cost ($US 674.8; 25.95660 QALYs [year 2012 values]). CXR was the 
      least cost-effective ($US 13,666.8; 24.62917 QALYs). Cost-effectiveness was 
      sensitive to adherence rate of 3HP and QFT specificity, but not to BCG 
      vaccination rate. CONCLUSIONS: Entry LTBI screening using QFT treated with 3HP is 
      recommended on the basis of cost effectiveness among long-term expatriates from 
      low to high incidence countries.
CI  - Copyright (c) 2016 Elsevier Ltd. All rights reserved.
FAU - Kowada, Akiko
AU  - Kowada A
AD  - General Affairs Department, Ota City Office, Tokyo, Japan. Electronic address: 
      kowadaa@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20160526
PL  - Netherlands
TA  - Travel Med Infect Dis
JT  - Travel medicine and infectious disease
JID - 101230758
RN  - V83O1VOZ8L (Isoniazid)
RN  - VJT6J7R4TR (Rifampin)
RN  - XJM390A33U (rifapentine)
SB  - IM
MH  - Adult
MH  - Computer Simulation
MH  - Cost-Benefit Analysis
MH  - Decision Trees
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Interferon-gamma Release Tests/*economics
MH  - Isoniazid/*therapeutic use
MH  - Latent Tuberculosis/*diagnosis/microbiology/transmission
MH  - Male
MH  - Markov Chains
MH  - Mass Screening
MH  - Rifampin/*analogs & derivatives/therapeutic use
MH  - *Travel
OTO - NOTNLM
OT  - Cost-effectiveness
OT  - Expatriate
OT  - Interferon-gamma release assay
OT  - Latent tuberculosis infection
OT  - Rifapentine
EDAT- 2016/10/25 06:00
MHDA- 2017/05/04 06:00
CRDT- 2016/05/31 06:00
PHST- 2014/03/09 00:00 [received]
PHST- 2016/04/10 00:00 [revised]
PHST- 2016/05/06 00:00 [accepted]
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
PHST- 2016/05/31 06:00 [entrez]
AID - S1477-8939(16)30043-6 [pii]
AID - 10.1016/j.tmaid.2016.05.010 [doi]
PST - ppublish
SO  - Travel Med Infect Dis. 2016 Sep-Oct;14(5):489-498. doi: 
      10.1016/j.tmaid.2016.05.010. Epub 2016 May 26.